Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Heart Failure × Ado-Trastuzumab Emtansine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 26 Carcinoma, Non-Small-Cell Lung 4 Urinary Bladder Neoplasms 2 Salivary Gland Neoplasms 2 Neoplasms 2 Neoplasm Metastasis 2 Colorectal Neoplasms 2 Wilms Tumor 1 Urologic Neoplasms 1 Triple Negative Breast Neoplasms 1 Solid Tumors 1 Sarcoma, Synovial 1 Rhabdomyosarcoma 1 Pleuropulmonary blastoma 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neurofibrosarcoma 1 Neuroblastoma 1 Multiple Myeloma 1 Metastatic HER2-positive Breast Cancer With Brain Metastasis 1 Lymphoma 1 Lung Neoplasms 1 Hematologic Neoplasms 1 Hemangiosarcoma 1 Heart Failure 1 HER2-positive Metastatic Breast Cancer 1 HER2-positive Breast Cancer 1 Genomic Instability 1 Gastrointestinal Neoplasms 1

Interventions

Control Groups 2 Atorvastatin 2 pertuzumab 1 nicotinamide-beta-riboside 1 empagliflozin 1 dapagliflozin 1 candesartan 1 Trastuzumab 1 Sodium Chloride 1 Simendan 1 Pyruvic Acid 1 Population Groups 1 Ogivri 1 Metoprolol 1 Hydroxymethylglutaryl-CoA Reductase Inhibitors 1 Eplerenone 1 Carvedilol 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04680442 2025-04-06

SCHOLAR-2

Population Health Research Institute

Phase 2 Recruiting

Breast Neoplasms, Heart Failure

Data powered by HemOnc (CC BY 4.0) Colophon ⚡